Tenax Therapeutics Working on Phase 2 Trial

- January 22nd, 2019

Anthony DiTonno, CEO of Tenax Therapeutics, talks about what’s on the horizon for financing and the development of the company’s drug.

Tenax Therapeutics (NASDAQ:TENX) is ready to begin enrolling patients in its pulmonary hypertension clinical trial. Anthony DiTonno, CEO of Tenax, told the Investing News Network about the company’s ongoing trial, the drug and financing.

DiTonno said the drug was developed by Orion Pharma in Finland, but is not available in the US. There is also no approved therapy for the indication. Tenax will enroll patients in the Phase 2 trial for pulmonary hypertension this quarter.

Topline results from the trial are expected by the end of the year. If positive, DiTonno said the company will meet with the US Food and Drug Administration (FDA) to design a Phase 3 trial for the drug.

  Life Science and Healthcare Investing report cover

Life Science and Healthcare Investing in 2021

The life science and healthcare market is a booming, multi-billion dollar industry. Read our 2021 life science outlook report!

The Phase 2 trial will enroll 36 patients over the course of the year and the trial will last six weeks. The company has already initiated five or six clinical sites for the trial to take place, which include “top rated institutions” he said. This consists of Mayo Clinic, Stanford University, North Western and more.

While the company is in early clinical development, DiTonno said there’s a significant body of evidence suggesting the drug is safe and effective for a variety of cardiovascular conditions.

The drug, levosimendan, is backed with 1,000 clinical citations, medical literature and 60 countries worth of approvals. It’s also already treated 1.5 million patients for acute decompensated heart failure. Tenax is developing the drug for pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF) in the US.

Tenax has previously developed the drug for cardiac surgery, and failed a Phase 3 clinical trial for the indication in January, 2017.

As for financing, DiTonno said the company’s current cash on hand coupled with a recently raised US$10 million will it “through the end of Phase 2 meetings.” In other words, until the end of 2019 and into the first quarter or so of 2020.

“We have the funds that is sufficient to fully enroll and analyze the data,” DiTonno said. This includes getting some initial feedback from the FDA, in terms of moving forward in Phase 3 trial.

It’s never a sure thing when companies go to raise money, DiTonno said, but there’s a potential additional US$10 to US$20 million that could come in for Tenax. For now, DiTonno said the company doesn’t see an “immediate need” to do any additional financing.

Check out the full interview with Tenax in the audio above from the Biotech Showcase 2019.

Don’t forget to follow @INN_LifeScience for real-time updates!

Securities Disclosure: I, Gabrielle Lakusta, hold no direct investment interest in any company mentioned in this article.

Editorial Disclosure: The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in the interviews it conducts. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.

  Life Science and Healthcare Investing in 2020 report cover

An Overview for Investors

COVID-19 continues to impact world markets. Get INN’s overview of coronavirus investing.

Get the latest Pharmaceutical Investing stock information

Get the latest information about companies associated with Pharmaceutical Investing Delivered directly to your inbox.

Pharmaceutical Investing

Select None
Select All

Leave a Reply